Vincerx Pharma Inc.

0.77
-0.32 (-29.36%)
At close: Mar 03, 2025, 3:59 PM
0.79
3.16%
After-hours: Mar 03, 2025, 05:59 PM EST

Company Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.

Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.

The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Vincerx Pharma Inc.
Vincerx Pharma Inc. logo
Country United States
IPO Date May 27, 2020
Industry Biotechnology
Sector Healthcare
Employees 42
CEO Dr. Raquel E. Izumi Ph.D.

Contact Details

Address:
260 Sheridan Avenue
Palo Alto, California
United States
Website https://vincerx.com

Stock Details

Ticker Symbol VINC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001796129
CUSIP Number 92731L106
ISIN Number US92731L1061
Employer ID 83-3197402
SIC Code 2834

Key Executives

Name Position
Dr. Raquel E. Izumi Ph.D. Co-Founder, Acting Chief Executive Officer, Secretary & Director
Kevin Haas Acting Chief Financial Officer, Vice President of Finance & Corporate Controller
Tom C. Thomas J.D. Founder, General Counsel & Chief Legal Officer
Dr. Ahmed M. Hamdy M.D. Co-Founder & Chairman
Dr. Beatrix Stelte-Ludwig Ph.D. Executive Chief Development Officer
Dr. Hans-Georg Lerchen Ph.D. Chief Scientific Officer
Dr. John C. Byrd M.D. Founder & Chairman of Scientific Advisory Board
Gabriela Jairala Vice President of Investor Relations & Corporate Communications and Chief of Staff
Karen Quarford M.B.A. Vice President of Quality Operations & Compliance
Melissa Merrick SPHR Senior Director of People & Culture and Head of Human Resource

Latest SEC Filings

Date Type Title
Feb 28, 2025 8-K Current Report
Feb 18, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 12, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 11, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 06, 2025 DEFA14A Filing
Feb 06, 2025 8-K Current Report
Jan 29, 2025 DEFA14A Filing
Jan 24, 2025 S-3 Filing
Jan 23, 2025 DEFA14A Filing